These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35100312)

  • 1. Model-based inference of neutralizing antibody avidities against influenza virus.
    Linnik J; Syedbasha M; Hollenstein Y; Halter J; Egli A; Stelling J
    PLoS Pathog; 2022 Jan; 18(1):e1010243. PubMed ID: 35100312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.
    To KK; Zhang AJ; Hung IF; Xu T; Ip WC; Wong RT; Ng JC; Chan JF; Chan KH; Yuen KY
    Clin Vaccine Immunol; 2012 Jul; 19(7):1012-8. PubMed ID: 22573737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.
    Liu X; Liu Y; Zhang Y; Chen Z; Tang Z; Xu Q; Wang Y; Zhao P; Qi Z
    PLoS One; 2013; 8(3):e58810. PubMed ID: 23527030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin.
    Schmeisser F; Friedman R; Besho J; Lugovtsev V; Soto J; Wang W; Weiss C; Williams O; Xie H; Ye Z; Weir JP
    Influenza Other Respir Viruses; 2013 May; 7(3):480-90. PubMed ID: 23122228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythrocyte binding preference of human pandemic influenza virus a and its effect on antibody response detection.
    Makkoch J; Prachayangprecha S; Payungporn S; Chieochansin T; Songserm T; Amonsin A; Poovorawan Y
    Ann Lab Med; 2012 Jul; 32(4):276-82. PubMed ID: 22779069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.
    Pedersen GK; Höschler K; Øie Solbak SM; Bredholt G; Pathirana RD; Afsar A; Breakwell L; Nøstbakken JK; Raae AJ; Brokstad KA; Sjursen H; Zambon M; Cox RJ
    Vaccine; 2014 Jul; 32(35):4550-4557. PubMed ID: 24950357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination.
    Gulati U; Kumari K; Wu W; Keitel WA; Air GM
    Vaccine; 2005 Feb; 23(11):1414-25. PubMed ID: 15661391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reaction but no avidity change of the serum antibody response after influenza vaccination.
    Brokstad KA; Cox RJ; Major D; Wood JM; Haaheim LR
    Vaccine; 1995 Nov; 13(16):1522-8. PubMed ID: 8578836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.
    Ferrara F; Del Rosario JMM; da Costa KAS; Kinsley R; Scott S; Fereidouni S; Thompson C; Kellam P; Gilbert S; Carnell G; Temperton N
    Front Immunol; 2021; 12():661379. PubMed ID: 34108964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.
    Yam KK; Gupta J; Brewer A; Scheifele DW; Halperin S; Ward BJ;
    Clin Vaccine Immunol; 2013 Apr; 20(4):459-67. PubMed ID: 23345582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
    Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
    Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency.
    Shen C; Zhang M; Chen Y; Zhang L; Wang G; Chen J; Chen S; Li Z; Wei F; Chen J; Yang K; Guo S; Wang Y; Zheng Q; Yu H; Luo W; Zhang J; Chen H; Chen Y; Xia N
    Theranostics; 2019; 9(1):210-231. PubMed ID: 30662563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus.
    Lemaitre M; Leruez-Ville M; De Lamballerie XN; Salez N; Garrone P; Fluckiger AC; Klatzmann D; Carrat F
    Clin Microbiol Infect; 2011 May; 17(5):732-7. PubMed ID: 20731679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gelatin particle agglutination (PA) antibody: comparison to neutralizing antibody (NT) and hemagglutination inhibition (HI) antibody and relationship to IgG avidity].
    Saika S; Matsunaga T; Ogawa T; Ichinohe S
    Kansenshogaku Zasshi; 2008 Jul; 82(4):310-6. PubMed ID: 18697482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.